Breaking News Instant updates and real-time market news.

CTLT

Catalent

$39.28

-0.23 (-0.58%)

, VWAGY

Volkswagen

$0.00

(0.00%)

19:33
04/14/19
04/14
19:33
04/14/19
19:33

Fly Intel: Top five weekend stock stories

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Catalent (CTLT) has agreed to buy closely held Paragon Bioservices for $1.2B, The Wall Street Journal's Jared Hopkins and Cara Lombardo reported, citing people familiar with the matter. The all-cash deal, which is expected to be announced Monday morning, would help Catalent expand its gene-therapy manufacturing capabilities, sources said. The transaction is expected to close in the second quarter, the publication added. 2. Volkswagen (VWAGY) plans to build a fully electric sports utility vehicle for China from 2021, taking on the Chinese market leader Tesla's (TSLA) Model X as the German carmaker ramps up production of zero emissions vehicles, Reuters' Edward Taylor reported. 3. CVS (CVS) should discuss its expansion plans for HealthHub at a June investor date, and while the stock has tumbled on stalled earnings growth and concerns that margins as a drug-price negotiator will fall, CVS' assets leave it "uniquely well positioned" for a future when consumers gain more control over healthcare and prices fall, Jack Hough wrote in this week's edition of Barron's. It might be time to buy the shares, Hough contended. 4. AT&T (T) subsidiary Warner Bros' "Shazam!" easily stayed number 1 in its second weekend, earning another $25.1M from 4,306 locations. The movie's 10-day domestic tally stands at $94.9M. Overseas, "Shazam!" also topped the chart with $35.9M for $258.8M globally. The pic sports an A CinemaScore and a 91% Rotten Tomatoes score. 5. Alcon (ALC), Huntington Bancshares (HBAN), KeyCorp (KEY), Valero Energy (VLO), PepsiCo (PEP), Medtronic (MDT), Pinterest (PINS), and Disney (DIS) saw positive mentions in Barron's.

CTLT

Catalent

$39.28

-0.23 (-0.58%)

VWAGY

Volkswagen

$0.00

(0.00%)

TSLA

Tesla

$267.66

-0.89 (-0.33%)

CVS

CVS Health

$52.81

0.09 (0.17%)

T

AT&T

$32.20

-0.01 (-0.03%)

ALC

Alcon

$54.49

-1.11 (-2.00%)

HBAN

Huntington Bancshares

$13.69

0.33 (2.47%)

KEY

KeyCorp

$16.88

0.44 (2.68%)

VLO

Valero

$88.40

-0.67 (-0.75%)

PEP

PepsiCo

$122.24

0.57 (0.47%)

MDT

Medtronic

$86.76

-0.84 (-0.96%)

PINS

Pinterest

$0.00

(0.00%)

DIS

Disney

$130.03

13.4 (11.49%)

  • 17

    Apr

  • 18

    Apr

  • 18

    Apr

  • 22

    Apr

  • 24

    Apr

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 30

    Apr

  • 01

    May

  • 01

    May

  • 01

    May

  • 06

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 08

    May

  • 13

    May

  • 18

    May

  • 20

    May

  • 23

    May

  • 29

    May

  • 30

    May

  • 31

    May

  • 18

    Apr

CTLT Catalent
$39.28

-0.23 (-0.58%)

11/15/18
BARD
11/15/18
INITIATION
Target $43
BARD
Outperform
Catalent initiated with an Outperform at Baird
Baird analyst Evan Stover initiated Catalent with an Outperform and $43 price target.
11/07/18
FANA
11/07/18
UPGRADE
Target $43
FANA
Outperform
Catalent upgraded to Outperform from Neutral at First Analysis
First Analysis analyst Steven Schwartz upgraded Catalent to Outperform while lowering his price target for the shares to $43 from $47. The analyst says that while management commentary following a "mixed" fiscal Q1 suggests more risk to near-term achievement of results, he remains confident in the company's medium- and long-term prospects based on a positive view of contract development and manufacturing organization industry dynamics. He upgrades the shares on valuation following yesterday's selloff.
10/09/18
UBSW
10/09/18
NO CHANGE
UBSW
UBS initiates coverage of Life Sciences and Diagnostics Tools sector
UBS analyst Daniel Brennan initiated coverage of the Life Sciences and Diagnostics Tools sector. He said demand is accelerating across his universe but valuations are extended. He expects strong fundamentals to continue into 2019 but he said selectivity is the key. In the group, his Buy ratings include Exact Sciences (EXAS), Iqvia (IQV), NanoString (NSTG), Syneos Health (SYNH) and Thermo Fisher (TMO).
03/05/19
FANA
03/05/19
NO CHANGE
Target $49
FANA
Outperform
Catalent price target raised to $49 from $46 at First Analysis
First Analysis analyst Steven Schwartz raised his price target for Catalent to $49 and maintains an Outperform rating on the shares following meetings with management. . The company has a "relatively modest" organic growth profile, but there is additional growth potential from margin expansion driven by business mix improvement and leverageable acquisitions, Schwartz tells investors in a research note.
VWAGY Volkswagen
$0.00

(0.00%)

04/11/19
ROTH
04/11/19
NO CHANGE
Target $240
ROTH
Neutral
Tesla price target lowered to $240 from $270 at Roth Capital
Roth Capital analyst Craig Irwin lowered his price target for Tesla (TSLA) to $240 from $270, while reiterating a Neutral rating on the shares. The analyst believes the direct read on Panasonic (PCRFY)/Tesla suspending plans for Gigafactory expansion is the partners probably do not see Tesla achieving projected sales volumes, and therefore necessary battery demand. The analyst thinks Tesla's battery costs are too high, with METI data pointing to Tesla's cell costs at around $240/kWh, while his checks show VW (VWAGY)/Porsche paying $250/kWh, indicating Tesla has no advantage here. Overall, Irwin believes Tesla's vehicle sales are slow because costs are simply too high for consumers.
04/02/19
JEFF
04/02/19
DOWNGRADE
JEFF
Hold
Volkswagen downgraded to Hold from Buy at Jefferies
Jefferies analyst Philippe Jean Houchois downgraded Volkswagen to Hold from Buy and lowered his price target for the shares to EUR 160 from EUR 180.
04/02/19
JEFF
04/02/19
NO CHANGE
JEFF
Jefferies discusses potential auto mergers, downgrades VW to Hold
The prospect of mergers in the automotive manufacturer space "tends to create excitement given how overdue it is," Jefferies analyst Philippe Houchois tells investors in a research note. Among the combinations being speculated in the press, the analyst views the logic and feasibility of a Fiat Chrysler (FCAU)/Peugeot (PUGOY) deal as "overwhelming." He rates both stocks a Buy. On the other hand, Houchois sees "limited rationale" in combining BMW (BMWYY) and Daimler AG's (DDAIF) Mercedes "as the challenge is to redefine, not bulk up, premium." Further, the analyst is not sure Volkswagen (VWGAY) can execute given its "governance/balance sheet." He downgrades the shares to Hold from Buy.
TSLA Tesla
$267.66

-0.89 (-0.33%)

04/09/19
NOMU
04/09/19
INITIATION
Target $300
NOMU
Neutral
Nomura Instinet starts 'true disruptor' Tesla with Neutral rating, $300 target
Nomura Instinet analyst Christopher Eberle initiated coverage of Tesla (TSLA) with a Neutral rating and $300 price target. The stock closed down 89c to $272.31. Tesla is a "true disruptor" of the automotive industry and its approach has "several moats," Eberle tells investors in a research note. The analyst, however, is cautious near term as Tesla navigates the "breakneck pace" of its global expansion. Eberle likens Tesla's position in electric vehicles and "Auto 2.0" to Salesforce (CRM) at the beginning of its software-as-a-service digital transformation era and its disruption of the way businesses bought and consumed software. Electric vehicle manufacturing and the selling of the cars are just the beginning of what CEO Elon Musk has in mind for Tesla, contends Eberle. He sees the company as "likely the foundation for automation of transportation."
04/09/19
LEHM
04/09/19
NO CHANGE
Target $192
LEHM
Underweight
Tesla's Q1 deliveries suggest 'demand cliff was real', says Barclays
Barclays analyst Brian Johnson kept his Underweight rating and $192 price target on Tesla, saying the company's Q1 deliveries reported last week suggests that the quarter will be "even tougher" than his below consensus view. The analyst notes that the price cuts announced in February reflects the view that the "demand cliff was real", and sees the deliveries print implying "further downside", particularly because of the shortfall in Model S and X vehicles. Johnson adds that a "meaningful rebound is unlikely", adding to Tesla's volume risks "at least until China production starts".
04/10/19
04/10/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with a Neutral at Nomura Instinet. 2. Community Healthcare (CHCT) initiated with an Outperform at Baird. 3. Community Bank System (CBU) initiated with an Equal Weight at Stephens. 4. Fox Corp re-initiated with a Market Perform at BMO Capital. 5. Wendy's (WEN) initiated with an Outperform at Cowen. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CVS CVS Health
$52.81

0.09 (0.17%)

04/11/19
04/11/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Lyft (LYFT) initiated with a Hold at HSBC. 2. Apple (AAPL), Dell Technologies (DELL), and HP Inc. (HPQ) initiated with a Neutral at Credit Suisse. 3. Yeti (YETI) initiated with an Outperform at Cowen. 4. CVS Health (CVS) initiated with a Market Perform at BMO Capital. 5. Canadian Solar (CSIQ) assumed with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/10/19
BMOC
04/10/19
INITIATION
BMOC
Market Perform
CVS Health initiated with a Market Perform at BMO Capital
BMO Capital analyst Matt Borsch initiated CVS Health with a Market Perform rating and a $58 price target. The analyst said that he is aware of the low valuation of the stock, but is "wary of further deterioration in the outlook given headwinds on CVS legacy businesses that have recently intensified," and is not confident "the pressures will diminish next year."
04/10/19
RHCO
04/10/19
NO CHANGE
RHCO
SunTrust lowers price targets on CVS, raises price target on WellCare
SunTrust analyst David MacDonald lowered his price target on CVS (CVS) to $65 from $85 as part of his broader research note previewing Q1 results for the healthcare services stocks. The analyst expects the quarter to reflect the company's challenges around reimbursement pressure, fewer generics, and lower brand inflation that should be a detriment to retail pharmacy and long-term-care businesses, even though he maintains a bullish view on the stock longer term based on its risk-reward profile. MacDonald also raises his price target on WellCare (WCG) to $340 from $305, saying his bullish expectation for the stock is driven by the company's "strong core trends, high visibility, and superb win rate". The analyst also cites the pending WellCare acquisition by Centene (CNC) yielding a "meaningful combined pharmacy opportunity and increased diversification" from an expanded "Medicaid footprint".
04/10/19
CANT
04/10/19
NO CHANGE
CANT
Senate hearing a net positive for PBMs, says Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper views yesterday's Senate hearing as a net positive for the pharmacy benefit managers. The PBMs represented were Cigna (CI), CVS Health (CVS), UnitedHealth (UNH), Humana (HUM) and Prime Therapeutics. Although the Senators were not supportive of the PBMs, the executives responded well to questions and put forth a solid effort to address concerns regarding their business model and incentives, Halper tells investors in a research note. Overall, he views the hearing as a net positive for PBMs "as the group was able to counter the negative sentiment with constructive responses, recognizing this story is far from over."
T AT&T
$32.20

-0.01 (-0.03%)

03/29/19
03/29/19
UPGRADE
Target $35

Buy
Viacom upgraded to Buy at Loop Capital on de-risked AT&T loss
As previously reported, Loop Capital analyst Alan Gould upgraded Viacom (VIAB) to Buy from Hold with a price target of $35. The analyst cites the company's loss of its biggest distributor AT&T (T) having been de-risked which, he believes, raises the likelihood of a Viacom merger with CBS (CBS). Gould adds that despite the renewed distribution deal with AT&T, investors can accumulate shares at a lower price than a few weeks ago, resulting in a "positive risk-reward" for Viacom.
03/15/19
03/15/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Amazon.com (AMZN) upgraded to Overweight from Sector Weight at KeyBanc with analyst Edward Yruma saying Amazon is taking a number of operational moves to improve profitability in core retail, which could drive mid-term earnings above current consensus estimates. 2. AT&T (T) upgraded to Outperform from Market Perform at Raymond James with analyst Frank Louthan saying AT&T shares trade at a relative discount and expects shares to be driven by positive earnings growth combined with a strong de-levering story. 3. Colfax (CFX) upgraded to Equal Weight from Underweight at Barclays with analyst Julian Mitchell saying he views the company's turnaround story as underappreciated. 4. Rent-A-Center (RCII) upgraded to Outperform from Market Perform at Raymond James with analyst Budd Bugatch citing the trial win regarding the terminated buyout with Vintage Capital and a strong fundamental outlook for the upgrade. 5. Global Net Lease (GNL) upgraded to Buy from Neutral at B. Riley FBR with analyst Bryan Maher citing the stock's attractive relative valuation as well as management's acquisition "acumen" for the upgrade to Buy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/27/19
JPMS
03/27/19
NO CHANGE
JPMS
Fundamentals across cable remain strong, says JPMorgan
Sustained household formation and wage growth, along with a pullback in promotional activity at AT&T (T), the main competitor to most multi-service operators, keeps fundamentals across cable strong, JPMorgan analyst Philip Cusick tells investors in a research note. In 2018, the U.S. added ~1.5m households for the second year in a row, "which sets up the wireline video and broadband ecosystems well in 2019," says the analyst. Altice USA (ATUS) and Charter Communications (CHTR) are both on the JPMorgan's Analyst Focus List, and Comcast (CMCSA) is Cusick's favorite mega-cap service provider. The analyst is "wary" of the multiple of Underweight-rated Cable One (CABO), but admits its operational momentum seems strong.
04/05/19
04/05/19
UPGRADE
Target $36

Outperform
Viacom upgraded to Outperform from Sector Perform at RBC Capital
As previously reported, RBC Capital analyst Steven Cahall upgraded Viacom (VIAB) to Outperform from Sector Perform and raised his price target to $36 from $31, saying the company's "less contentious" than feared DirecTV (T) deal improves its standing and "paves the way toward merger talks" with CBS (CBS). The analyst sees an implied upside for Viacom stock at over 30% on the CBS deal prospects and believes that investors should own both to hedge the exchange ratio risk of the potential transaction.
ALC Alcon
$54.49

-1.11 (-2.00%)

04/11/19
SOCG
04/11/19
DOWNGRADE
SOCG
Sell
Societe Generale corrects error in work, downgrades Alcon to Sell
Societe Generale analyst Delphine Le Louet, who initiated Alcon yesterday with a Buy rating and CHF67 price target, said she identified an error in her model and has downgraded the stock to Sell from Buy after correcting her work. Her corrected discounted cash flow valuation analysis leads her to a new price target of CHF44, said the analyst, who apologized for the error and noted she made no changes to her P&L forecasts.
04/11/19
SOCG
04/11/19
DOWNGRADE
SOCG
Sell
Alcon downgraded to Sell from Buy at Societe Generale
04/10/19
BREN
04/10/19
INITIATION
BREN
Hold
Alcon initiated with a Hold at Berenberg
Berenberg analyst Scott Bardo initiated Alcon with a Hold citing valuation.
04/10/19
SOCG
04/10/19
INITIATION
SOCG
Buy
Alcon initiated with a Buy at Societe Generale
HBAN Huntington Bancshares
$13.69

0.33 (2.47%)

04/04/19
GSCO
04/04/19
DOWNGRADE
Target $84
GSCO
Neutral
Goldman downgrades Comerica to Neutral from Buy as rate hikes wane
Goldman Sachs analyst Ryan Nash downgraded Comerica (CMA) to Neutral from Buy and lowered his price target for the shares to $84 from $89. While loan growth has begun to improve from the lows, a lack of additional interest rate hikes, along with more exposure to consumer deposits continuing to re-price higher, likely means that the company's margins will begin to compress beyond Q1, Nash tells investors in a research note. He believes this will "pressure" consensus estimates. In the Regional Banks space, the analyst is most upbeat on Signature Bank (SBNY), Citizens Financial (CFG) and Cadence Bancorp (CADE) into Q1. He's less optimistic on First Horizon (FHN) and Huntington Bancshares (HBAN).
01/28/19
JEFF
01/28/19
DOWNGRADE
Target $14
JEFF
Hold
Huntington Bancshares downgraded to Hold from Buy at Jefferies
Jefferies analyst Kenneth Usdin downgraded Huntington Bancshares to Hold with a $14 price target following the company's Q4 results. Negative earnings revisions overcome Huntington's better loan and deposit growth, Usdin tells investors in a research note.
11/29/18
SDLR
11/29/18
DOWNGRADE
SDLR
Hold
Huntington Bancshares downgraded to Hold from Buy at Sandler O'Neill
11/29/18
SDLR
11/29/18
DOWNGRADE
Target $16
SDLR
Hold
Huntington Bancshares downgraded to Hold on valuation at Sandler O'Neill
As previously reported, Sandler O'Neill analyst R. Scott Siefers downgraded Huntington Bancshares to Hold from Buy, stating that he sees the shares "deservedly holding their established premium multiple" from here, but he does not necessarily see that premium expanding meaningfully given the stock's recent relative outperformance compared to other large regional banks. He has a $16 price target for Huntington Bancshares.
KEY KeyCorp
$16.88

0.44 (2.68%)

03/29/19
03/29/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wells Fargo (WFC) upgraded to Market Perform from Underperform at Raymond James with analyst David Long saying the retirement of CEO Tim Sloan removes a "headwind." 2. Viacom (VIA, VIAB) upgraded to Buy from Hold at Loop Capital with analyst Alan Gould citing the company's loss of its biggest distributor AT&T (T) having been de-risked which, he believes, raises the likelihood of a Viacom merger with CBS (CBS). 3. F5 Networks (FFIV) upgraded to Neutral from Underweight at Piper Jaffray with analyst James Fish saying after underperforming the tech sector and the market over the last six months by ~20%, some of the main downside share catalysts have played out. 4. Mosaic (MOS) upgraded to Neutral from Underperform at Credit Suisse with analyst Chris Parkinson citing modest downside to Chinese cash operating costs, lower immediate-term ammonia and sulfur costs, evidence of near-term volume discipline, the emphasis on long-term cost reduction programs and balance sheet stability. 5. KeyCorp (KEY) upgraded to Neutral from Reduce at Nomura Instinet with analyst Bill Carcache saying he believes the shares are near a fair valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/04/19
JPMS
04/04/19
DOWNGRADE
Target $17
JPMS
Neutral
KeyCorp downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Steven Alexopoulos downgraded KeyCorp to Neutral from Overweight and lowered his price target for the shares to $17 from $18.
03/29/19
NOMU
03/29/19
UPGRADE
Target $16
NOMU
Neutral
KeyCorp upgraded to Neutral from Reduce at Nomura Instinet
Nomura Instinet analyst Bill Carcache upgraded KeyCorp to Neutral from Reduce with an unchanged price target of $16. The analyst believes the shares are near a fair valuation.
04/04/19
JPMS
04/04/19
NO CHANGE
JPMS
JPMorgan downgrades Comerica, Zions and KeyCorp, upgrades Signature Bank
In an attempt to reduce interest rate "sensitivity," JPMorgan analyst Steven Alexopoulos downgraded Comerica (CMA), Zions Bancorp (ZION) and KeyCorp (KEY) to Neutral from Overweight and upgraded Signature Bank (SBNY) to Overweight from Neutral. The analyst says his bearish call on the bank sector "remains fully intact" even though the stock are "technically now much cheaper" since his October 2018 call. The tailwinds that helped bottom line growth for banks over the past several years will "fully start transitioning into headwinds" during 2019, Alexopoulos tells investors in a research note. He suggests repositioning portfolios away from asset sensitive banks while simultaneously increasing exposure to liability sensitive banks.
VLO Valero
$88.40

-0.67 (-0.75%)

03/25/19
FBCO
03/25/19
NO CHANGE
Target $105
FBCO
Outperform
Valero added to Top Picks list at Credit Suisse
Credit Suisse analyst Manav Gupta added Valero to his firm's Top Picks list as he sees the company best positioned to benefit from a rebound in refining cracks. In the near/medium term, the analyst believes unplanned downtime at peers, startup of multiple Permian pipes, Canada adding rail capacity to GC, and higher distillate margins driven by IMO 2020 should all act as catalyst for Valero. Longer term, the new Coker project and DGT add meaningful earnings upside, he contends. Gupta reiterates an Outperform rating and a $105 price target on the shares.
03/08/19
WOLF
03/08/19
UPGRADE
WOLF
Outperform
Valero upgraded to Outperform from Peer Perform at Wolfe Research
01/25/19
GSCO
01/25/19
UPGRADE
Target $84
GSCO
Neutral
Valero upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Neil Mehta upgraded Valero Energy to Neutral and raised his price target for the shares to $84 from $72. The analyst is more positive on the shares given the company's free cash flow and he sees a more balanced risk/reward following the recent underperformance.
02/21/19
STPT
02/21/19
DOWNGRADE
STPT
Hold
Valero downgraded to Hold from Buy at Standpoint Research
PEP PepsiCo
$122.24

0.57 (0.47%)

03/07/19
FBCO
03/07/19
INITIATION
FBCO
Credit Suisse starts Household Products & Beverages with Constellation top pick
Credit Suisse analyst Kaumil Gajrawala rolled out coverage last night on eight names in the Household Products & Beverages space. The analyst's ratings consist of three Outperforms, two Underperforms, and three Neutrals. His top pick is Constellation Brands (STZ), which he started with an Outperform rating and $230 price target. The company offers "predictable" high-single digit revenue growth with a valuation that is "well below slower growth peers," Gajrawala tells investors in a research note. His other Outperform ratings are on Monster Beverage (MNST) and Clorox (CLX). The analyst has a $78 price target on Monster, noting it is the fastest growing company in his coverage "with runway for continued growth." He has a $172 price target on Clorox saying the company's "unique" portfolio position justifies a premium valuation. Gajrawala's Neutral rated names are Church & Dwight (CHD), Procter & Gamble (PG) and Coca-Cola (KO). His two Underperforms are PepsiCo (PEP) and Colgate-Palmolive (CL). PepsiCo has a $100 price target as the analyst sees limited upside amid the company's "stepped-up" investment years. Colgate-Palmolive, Gajrawala's less favorite name, has a $55 price target. The company's out-year margins are at risk as it reinvests to address several years of slowing growth and sales declines, Gajrawala contends.
03/11/19
STFL
03/11/19
NO CHANGE
Target $67
STFL
Buy
Hypothetical Bang sale more negative than positive for Monster, says Stifel
Stifel analyst Mark Astrachan examined the hypothetical impact on Monster Beverage (MNST) should a larger beverages competitor acquire Bang, though he noted he has no knowledge of M&A negotiations or discussions with the energy drink competitor. He ultimately concluded a potential acquisition of Bang would be more negative than positive for Monster, though he also noted that risks of an acquisition include potential disruption of Bang's recent momentum, especially if it were to be acquired by PepsiCo (PEP) and transition distribution most likely in-house from the AB InBev (BUD) system. Additionally, a theoretical Bang deal could accelerate a decision by Coca-Cola (KO) regarding acquiring, or not, the remaining shares in Monster it does not currently own, said Astrachan, who keeps a Buy rating and $67 price target on Monster Beverage shares.
03/07/19
03/07/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Five Below (FIVE) initiated with an Outperform at Oppenheimer. 2. Teva (TEVA) reinstated with a Buy at UBS. 3. Chiasma (CHMA) initiated with an Overweight at Cantor Fitzgerald. 4. Monster Beverage (MNST) and Constellation Brands (STZ) were initiated with an Outperform at Credit Suisse, while Procter & Gamble (PG), Coca-Cola (KO), and Church & Dwight (CHD) were initiated with a Neutral, and PepsiCo (PEP), Colgate-Palmolive (CL), and Clorox (CLX) initiated with an Underperform at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/11/19
MSCO
04/11/19
DOWNGRADE
Target $24
MSCO
Underweight
Morgan Stanley downgrades Keurig Dr Pepper to Underweight on coffee risk
As previously reported, Morgan Stanley analyst Dara Mohsenian downgraded Keurig Dr Pepper to Underweight from Equal Weight as he sees a negative risk-reward despite a "well telegraphed" Q1 earnings beat on strong pricing at heritage Dr. Pepper Snapple. Based on the firm's recent AlphaWise survey, the analyst sees risk to coffee growth, noting that his forecast of around 1.5% is below the market-implied 4% long-term coffee topline growth, which is a key driver of his EPS forecast by 2021 being 5% below consensus. Additionally, Keurig Dr Pepper shares trade at a premium to the average of beverage peers Coca-Cola (KO) and PepsiCo (PEP) despite lower expected long-term topline growth, Mohsenian noted. He cut his price target on Keurig Dr Pepper shares to $24 from $27.
MDT Medtronic
$86.76

-0.84 (-0.96%)

04/09/19
SPHN
04/09/19
NO CHANGE
Target $170
SPHN
Overweight
Medtronic outcomes-based program could be headwind for DexCom, says Stephens
After Medtronic (MDT) announced that the company has reached a deal with Blue Cross and Blue Shield of Minnesota on an outcomes-based program for the company's Guardian Connect Continuous Glucose Monitoring system, Stephens analyst Chris Cooley said the program could potentially represent an incremental headwind to Dexcom's (DXCM) revenue growth if applied across a larger setting. However, Cooley is maintaining his calendar 2019 and 2020 estimates for Dexcom and keeps an Overweight rating on shares with a $170 price target.
03/18/19
WELS
03/18/19
NO CHANGE
Target $202
WELS
Outperform
Edwards Lifesciences price target raised to $202 from $188 at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen raised his price target for Edwards Lifesciences to $202 from $188 after the results of the company's low-risk TAVR trial was presented at the 2019 American College of Cardiology meeting. The analyst sees potential upside to his forecast given the strong low-risk results presented at ACC. Biegelsen reiterates an Outperform rating on the shares.
03/29/19
STFL
03/29/19
NO CHANGE
Target $45
STFL
Buy
IntriCon added to Select List at Stifel
Stifel analyst Jonathan Block said "the past twelve months have certainly been eventful" for IntriCon (IIN) but he contends that the company is "in a much more formidable place than where they were 12 months ago." In terms of potential catalysts over the next twelve months, Block points to a formalization of the company's contract with Medtronic (MDT), changes to the board, the international rollout of 670G and his expectation for a more aggressive Guardian CGM launch in mid-2019. Block, who believes the stock can double from current levels, added IntriCon to the Stifel Select List and keeps a Buy rating and $45 price target on the shares.
03/18/19
ADAM
03/18/19
NO CHANGE
Target $215
ADAM
Buy
Edwards Lifesciences price target raised to $215 from $190 at Canaccord
Canaccord analyst Jason Mills maintained a Buy rating on Edwards Lifesciences (EW) and raised his price target to $215 from $190 after the PARTNER 3 trial delivered superiority to surgery. In a research note to investors, Mills says he thinks the data will give Edwards a definitive marketing advantage in the TAVRmarket, relative to both Medtronic (MDT) and Boston Scientific (BSX), he thinks now has a higher hurdle to clear in TAVR than pre-Phase 3 data release.
PINS Pinterest
$0.00

(0.00%)

04/09/19
ATLE
04/09/19
INITIATION
Target $23
ATLE
Overweight
Pinterest initiated with an Overweight at Atlantic Equities
Atlantic Equities analyst James Coredwell initiated Pinterest with an Overweight and $23 price target.
04/09/19
ATLE
04/09/19
INITIATION
Target $23
ATLE
Overweight
Atlantic bullish on Pinterest pre-IPO, calls valuation 'not challenging'
Atlantic Equities analyst James Cordwell earlier today initiated coverage of upcoming initial public offering Pinterest (PINS) with an Overweight rating and $23 price target. The company's 75M share IPO is expected to price between $15 and $17 per share. Pinterest's "unique and broadly appealing" proposition, which offers consumers the ability to view and collate visual recommendations, will enable "ongoing robust" user growth, Cordwell told investors in a research note. Further, the analyst expects "significant" monetization upside due to Pinterest's higher purchasing intent of the user base along with a lower current average revenue per user than other advertising-supported platform. Pinterest offers an attractive way to "diversify online advertising exposure" with non-GAAP profitability coming this year 2019 and a "not challenging" valuation, contends Cordwell.
DIS Disney
$130.03

13.4 (11.49%)

04/12/19
04/12/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Redfin (RDFN) initiated with an Outperform at Wedbush. 2. Autodesk (ADSK) initiated with a Buy at Mizuho. 3. Upwork (UPWK) initiated with a Buy at BTIG. 4. Otter Tail (OTTR) initiated with a Buy at Maxim. 5. Disney (DIS) reinstated with an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/12/19
RHCO
04/12/19
NO CHANGE
RHCO
Disney+ not a 'strong alternative' to Netflix, says SunTrust
SunTrust analyst Matthew Thornton keeps his Buy rating on Netflix (NFLX) after Disney's (DIS) Disney+ investor day presentation, saying that while he continues to view the platform posing incremental competition for new subscriber adds, he expects it to be "manageable". The analyst notes that the Disney+ event contained "no big surprises in terms of pricing, timing, availability, and content", adding that the accelerated cord-cutting from the launch should also be positive for Netflix, which offers a "much broader range of content". Thornton further states that Disney+ should be a "modest incremental positive" for his Buy-rated Roku (ROKU) as it will be available for sale on its platform given its "potential for direct monetization."
04/12/19
RBCM
04/12/19
NO CHANGE
Target $140
RBCM
Top Pick
Disney+ content, ARPU 'compelling', says RBC Capital
RBC Capital analyst Steven Cahall kept his Top Pick rating and $140 price target on Disney after its Investor Day, saying the presentation "exceeded expectations and should turn sentiment bullish." The analyst sees Disney+ content and expectations of average revenue per user as "compelling" while noting that the guidance for subscribers was "significantly higher" than expected. Cahall believes that Disney stock can rise above $130 "in short order" and extend gains to $140 within the next 12 months.
04/12/19
MSCO
04/12/19
NO CHANGE
Target $135
MSCO
Overweight
Morgan Stanley says Disney+ sub outlook, profitability path better than expected
Morgan Stanley analyst Benjamin Swinburne said Disney's (DIS) target for 60M-90M Disney+ subscribers by year-end 2024 was well above his prior 30M subscriber expectation and that the company's guidance for roughly 110M-160M subscriptions for its three major OTT subscription services by 2024 was also well ahead of his forecast for just over 90M. Profitability by FY24 is also earlier than his expectations, noted Swinburne, who believes Disney's expected timeline for DTC profitability has positive implications for long-term EPS. While there may be short-term pressure on Netflix (NFLX) following the Disney investor day, Swinburne advises investors use any selloff as a buying opportunity, citing his view that Netflix will still be offering greater breadth and volume of content. The analyst keeps Overweight ratings on Disney and Netflix shares.

TODAY'S FREE FLY STORIES

PINS

Pinterest

$24.46

(0.00%)

13:04
04/20/19
04/20
13:04
04/20/19
13:04
Periodicals
Pinterest stock is hot after IPO, investors should keep cool, Barron's says »

Pinterest priced its IPO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

HUM

Humana

$240.65

7.645 (3.28%)

, CI

Cigna

$148.95

3.46 (2.38%)

12:51
04/20/19
04/20
12:51
04/20/19
12:51
Periodicals
Health insurers stocks now look like a buy, Barron's says »

Investing in health…

HUM

Humana

$240.65

7.645 (3.28%)

CI

Cigna

$148.95

3.46 (2.38%)

ANTM

Anthem

$239.63

3.38 (1.43%)

UNH

UnitedHealth

$221.74

4.93 (2.27%)

CVS

CVS Health

$52.62

0.08 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 30

    Apr

  • 01

    May

  • 01

    May

  • 02

    May

  • 07

    May

  • 15

    May

  • 16

    May

  • 19

    May

  • 22

    May

  • 23

    May

  • 29

    May

  • 18

    Jun

  • 13

    Nov

TSLA

Tesla

$273.25

2.13 (0.79%)

12:49
04/20/19
04/20
12:49
04/20/19
12:49
Hot Stocks
Tesla says four board members agreed to not stand for re-election »

Tesla disclosed late…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

AMD

AMD

$27.68

0.18 (0.65%)

, INTC

Intel

$58.49

-0.08 (-0.14%)

12:43
04/20/19
04/20
12:43
04/20/19
12:43
Periodicals
Wall Street cheered Intel decision to exit 5G modem business, Barron's says »

Apple (AAPL) and Qualcomm…

AMD

AMD

$27.68

0.18 (0.65%)

INTC

Intel

$58.49

-0.08 (-0.14%)

QCOM

Qualcomm

$79.89

0.8 (1.01%)

AAPL

Apple

$203.83

0.69 (0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    Apr

  • 30

    Apr

  • 01

    May

  • 08

    May

  • 15

    May

  • 16

    May

  • 03

    Jun

  • 03

    Jun

SAM

Boston Beer

$266.90

0.89 (0.33%)

12:37
04/20/19
04/20
12:37
04/20/19
12:37
Periodicals
'Happy hour' might be over for Boston Beer, Barron's says »

Boston Beer's shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 16

    May

SPOT

Spotify

$139.53

1.88 (1.37%)

12:30
04/20/19
04/20
12:30
04/20/19
12:30
Periodicals
Spotify stock 'risky' as music industry not changing fast enough, Barron's says »

Spotify might end up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

BA

Boeing

$380.02

2.48 (0.66%)

, HRL

Hormel Foods

$40.38

-0.37 (-0.91%)

08:33
04/20/19
04/20
08:33
04/20/19
08:33
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

BA

Boeing

$380.02

2.48 (0.66%)

HRL

Hormel Foods

$40.38

-0.37 (-0.91%)

PPC

Pilgrim's Pride

$25.79

0.03 (0.12%)

SAFM

Sanderson Farms

$141.70

-2.17 (-1.51%)

TSN

Tyson Foods

$73.49

0.2 (0.27%)

CCL

Carnival

$53.64

-0.92 (-1.69%)

RCL

Royal Caribbean

$121.00

-2.245 (-1.82%)

NCLH

Norwegian Cruise Line

$56.93

-0.925 (-1.60%)

WFTBF

West Fraser Timber

$0.00

(0.00%)

IFSPF

Interfor

$0.00

(0.00%)

CFPZF

Canfor

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 29

    Apr

  • 01

    May

  • 02

    May

  • 06

    May

  • 18

    May

  • 28

    May

  • 29

    May

  • 29

    May

  • 05

    Jun

  • 13

    Nov

MSM

MSC Industrial

$83.37

-0.44 (-0.52%)

04:55
04/20/19
04/20
04:55
04/20/19
04:55
Conference/Events
MSC Industrial management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 21

    Apr

  • 22

    Apr

  • 23

    Apr

  • 24

    Apr

  • 05

    Jun

  • 13

    Nov

KFS

Kingsway Financial

$2.30

-0.14 (-5.74%)

19:48
04/19/19
04/19
19:48
04/19/19
19:48
Hot Stocks
Kingsway Financial announces receipt of notification letter from NYSE »

Kingsway Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWK

American Water

$104.63

2.32 (2.27%)

19:46
04/19/19
04/19
19:46
04/19/19
19:46
Hot Stocks
American Water signs contract to acquire East Pasadena Water Company »

California American…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 10

    May

FSNN

Fusion

$0.24

0.0048 (2.01%)

19:45
04/19/19
04/19
19:45
04/19/19
19:45
Hot Stocks
Fusion sees being delisted following receipt of Nasdaq delisting notice »

Fusion announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 30

    May

PSA

Public Storage

$217.43

0.81 (0.37%)

19:42
04/19/19
04/19
19:42
04/19/19
19:42
Hot Stocks
Public Storage announces change of Chief Legal Officer »

Public Storage announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 02

    May

  • 04

    Jun

V

Visa

$160.14

-0.33 (-0.21%)

19:40
04/19/19
04/19
19:40
04/19/19
19:40
Hot Stocks
Visa board elects Visa CEO Al Kelly as Chair »

Visa announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 09

    May

  • 29

    May

  • 05

    Jun

NAVB

Navidea

$0.17

0.0001 (0.06%)

19:39
04/19/19
04/19
19:39
04/19/19
19:39
Hot Stocks
Navidea announces one-for-twenty reverse stock split »

Navidea…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TISA

Top Image Systems

$0.84

-0.0069 (-0.81%)

19:37
04/19/19
04/19
19:37
04/19/19
19:37
Hot Stocks
Top Image sees voluntarily delisting to be complete before Nasdaq deadline »

Top Image Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCPT

Four Corners Property Trust

$28.17

0.49 (1.77%)

19:33
04/19/19
04/19
19:33
04/19/19
19:33
Hot Stocks
Four Corners Property Trust acquires restaurant properties for $2.6M »

Four Corners Property…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

PRK

Park National

$93.98

-2.72 (-2.81%)

19:32
04/19/19
04/19
19:32
04/19/19
19:32
Earnings
Park National reports Q1 EPS $1.62, two estimates $1.61 »

Commercial loans grew…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 29

    May

STNE

StoneCo

$26.50

-8.25 (-23.74%)

19:29
04/19/19
04/19
19:29
04/19/19
19:29
Hot Stocks
StoneCo says latest incentive offers from competitors don't change strategy »

StoneCo released a CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

GPIC

Gaming Partners

$13.09

(0.00%)

19:24
04/19/19
04/19
19:24
04/19/19
19:24
Hot Stocks
Gaming Partners sees acquisition by Angel closing on May 1 »

Gaming Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHW

Charles Schwab

$45.57

-0.53 (-1.15%)

17:04
04/19/19
04/19
17:04
04/19/19
17:04
Conference/Events
Charles Schwab to hold a webcast »

Management holds a 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 15

    May

12:45
04/19/19
04/19
12:45
04/19/19
12:45
General news
Breaking General news story  »

Week of 4/19 Baker-Hughes…

MMNFF

MedMen

$0.00

(0.00%)

11:13
04/19/19
04/19
11:13
04/19/19
11:13
Hot Stocks
MedMen announces resignations of COO and General Counsel »

MedMen Enterprises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TKC

Turkcell

$5.49

-0.175 (-3.09%)

11:08
04/19/19
04/19
11:08
04/19/19
11:08
Hot Stocks
Turkcell sees conclusion of $4.2B lawsuit against MTN this year »

The following statement…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCCY

1st Constitution Bancorp

$18.07

-0.14 (-0.77%)

11:05
04/19/19
04/19
11:05
04/19/19
11:05
Earnings
1st Constitution Bancorp reports Q1 EPS 39c, two estimates 36c »

Robert Mangano, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QUMU

Qumu

$2.83

-0.035 (-1.22%)

11:03
04/19/19
04/19
11:03
04/19/19
11:03
Hot Stocks
Qumu announces death of director Thomas Madison »

Qumu Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 09

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.